Program
Maraviroc
Also written as “Maraviroc (UK-427,857)”, “maraviroc” and “Maraviroc + Fosamprenavir/ritonavir”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · HIV Infections · Post-Acute COVID-19 Syndrome · Infections · Arthritis, Rheumatoid, led by 4 companies.
Drug pageMaraviroc: every studyAll 118 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 220 open or running | phase 4since Apr 23, 2008 | Dec 6, 2004 | none ahead |
| Pfizerits history only | 20 open or running | phase 2since Jan 25, 2007 | Jan 25, 2007 | none ahead |
| HealthBio | 11 open or running | phase 3since May 7, 2025 | May 7, 2025 | Dec 1, 2026phase 3 · NCT06974084 |
| Population Councilits history only | 10 open or running | phase 1since Jan 20, 2015 | Jan 20, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of HealthBio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2025First study: phase 3 study in Post-Acute COVID-19 SyndromeFirst studyNCT06974084 · 252 planned · United States
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Post-Acute COVID-19 SyndromeNCT06974084
TargetBeta
“A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV)”NCIt, by rule
“C-C chemokine receptor type 5 antagonist”ChEMBL 37, by rule
Other programs on CCR5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| leronlimabrule | CytoDyn | phase 3 | 20 |
Studies
The one study HealthBio leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06974084Post-Acute COVID-19 Syndrome · United States | 3 | Not yet recruiting | Dec 1, 2026 | 252 |
How it is read
Names in the registry
- “Maraviroc”, 23 entries
- “Maraviroc (UK-427,857)”, 8 entries
- “maraviroc”, 5 entries
- “Maraviroc + Fosamprenavir/ritonavir”, 4 entries
- “Maraviroc +PF-03716539”, 2 entries
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 10 studies
- HIV Infections, 7 studies
- Post-Acute COVID-19 Syndrome, 1 study
- Infections, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.